(3)Commission Implementing Regulation (EU) 2023/2592note extended the approval period of the active substance fenpyrazamine until 31 May 2026 and Commission Implementing Regulation (EU) 2023/1757note extended the approval period of the active substance flumetralin until 11 May 2026, pending the remaining steps in the procedure for the renewal of the approval of those active substances.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.